SPY396.32-12.00 -2.94%
DIA319.03-8.07 -2.47%
IXIC11,563.60-420.93 -3.51%

Abeona Therapeutics Highlights Presentation Of Data On Its Novel Capsid Candidate At Association For Research In Vision, Ophthalmology Meeting May 3 At 5:30-7:30 p.m. EDT

Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in cell and gene therapy, today announced that preclinical data on AAV204, a novel adeno-associated virus (AAV) capsid from Abeona’s in-licensed

Benzinga · 04/29/2022 09:12

Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in cell and gene therapy, today announced that preclinical data on AAV204, a novel adeno-associated virus (AAV) capsid from Abeona’s in-licensed AIM™ capsid library, will be presented at the Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting, to be held on May 1-4, 2022 in Denver, CO and virtually on May 11-12, 2022.

The poster presentation will highlight the ability of AAV204 to produce more robust transduction in the macula area of the eye following para-retinal administration in non-human primates, an ocular administration method that does not require a subretinal detachment. The presentation details are as follows:

Posterboard Number: 3170-F0444
Title: AAV204, a Novel AAV Capsid, Demonstrates Superior Macular Transduction Following Para-Retinal Administration in Non-human Primates
Presenter: Brian Kevany Ph.D., Chief Technical Officer and Head of Research at Abeona
Poster Session Date/Times: Tuesday, May 3, 2022, from 5:30-7:30 PM MDT